Cargando…

Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy

BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicar...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagawa, Shigeru, Domae, Keitaro, Yoshikawa, Yasushi, Fukushima, Satsuki, Nakamura, Teruya, Saito, Atsuhiro, Sakata, Yasushi, Hamada, Seiki, Toda, Koichi, Pak, Kyongsun, Takeuchi, Masahiro, Sawa, Yoshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532985/
https://www.ncbi.nlm.nih.gov/pubmed/28381469
http://dx.doi.org/10.1161/JAHA.116.003918
_version_ 1783253556423294976
author Miyagawa, Shigeru
Domae, Keitaro
Yoshikawa, Yasushi
Fukushima, Satsuki
Nakamura, Teruya
Saito, Atsuhiro
Sakata, Yasushi
Hamada, Seiki
Toda, Koichi
Pak, Kyongsun
Takeuchi, Masahiro
Sawa, Yoshiki
author_facet Miyagawa, Shigeru
Domae, Keitaro
Yoshikawa, Yasushi
Fukushima, Satsuki
Nakamura, Teruya
Saito, Atsuhiro
Sakata, Yasushi
Hamada, Seiki
Toda, Koichi
Pak, Kyongsun
Takeuchi, Masahiro
Sawa, Yoshiki
author_sort Miyagawa, Shigeru
collection PubMed
description BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicardial surface to maximize paracrine effects. This Phase I clinical trial tested whether transplanting autologous cell–sheets derived from skeletal muscle is feasible, safe, and effective for treating severe congestive heart failure. METHODS AND RESULTS: Fifteen ischemic cardiomyopathy patients and 12 patients with dilated cardiomyopathy, who were in New York Heart Association functional class II or III and had been treated with the maximum medical and/or interventional therapies available, were enrolled. Scaffold‐free cell sheets of 3 to 9×10(8) cells derived from autologous muscle were transplanted over the LV free wall via left thoracotomy, without additional interventional treatments. There were no procedure‐related major complications during follow‐up. The majority of the ischemic cardiomyopathy patients showed marked symptomatic improvement in New York Heart Association classification (pre: 2.9±0.5 versus 6 months: 2.1±0.4, P<0.01; 1 year: 1.9±0.3, P<0.01) and the Six‐Minute Walk Test with significant reduction of serum brain natriuretic peptide level (pre: 308±72 pg/mL versus 6 months: 191±56 versus 1 year: 182±46, P<0.05), pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary vein resistance, and left ventricular wall stress after transplantation instead of limited efficacy in dilated cardiomyopathy patients. CONCLUSIONS: Cell‐sheet transplantation as a sole therapy was feasible for treating cardiomyopathy. Promising results in the safety and functional recovery warrant further clinical follow‐up and larger studies to confirm this treatment's efficacy for severe congestive heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/english/. Unique identifier: UMIN000003273.
format Online
Article
Text
id pubmed-5532985
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55329852017-08-14 Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy Miyagawa, Shigeru Domae, Keitaro Yoshikawa, Yasushi Fukushima, Satsuki Nakamura, Teruya Saito, Atsuhiro Sakata, Yasushi Hamada, Seiki Toda, Koichi Pak, Kyongsun Takeuchi, Masahiro Sawa, Yoshiki J Am Heart Assoc Original Research BACKGROUND: When transplanted into failing heart, autologous somatic tissue–derived cells yield functional recovery via paracrine effects that enhance native regeneration. However, the therapeutic effects are modest. We developed a method in which scaffold‐free cell sheets are attached to the epicardial surface to maximize paracrine effects. This Phase I clinical trial tested whether transplanting autologous cell–sheets derived from skeletal muscle is feasible, safe, and effective for treating severe congestive heart failure. METHODS AND RESULTS: Fifteen ischemic cardiomyopathy patients and 12 patients with dilated cardiomyopathy, who were in New York Heart Association functional class II or III and had been treated with the maximum medical and/or interventional therapies available, were enrolled. Scaffold‐free cell sheets of 3 to 9×10(8) cells derived from autologous muscle were transplanted over the LV free wall via left thoracotomy, without additional interventional treatments. There were no procedure‐related major complications during follow‐up. The majority of the ischemic cardiomyopathy patients showed marked symptomatic improvement in New York Heart Association classification (pre: 2.9±0.5 versus 6 months: 2.1±0.4, P<0.01; 1 year: 1.9±0.3, P<0.01) and the Six‐Minute Walk Test with significant reduction of serum brain natriuretic peptide level (pre: 308±72 pg/mL versus 6 months: 191±56 versus 1 year: 182±46, P<0.05), pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary vein resistance, and left ventricular wall stress after transplantation instead of limited efficacy in dilated cardiomyopathy patients. CONCLUSIONS: Cell‐sheet transplantation as a sole therapy was feasible for treating cardiomyopathy. Promising results in the safety and functional recovery warrant further clinical follow‐up and larger studies to confirm this treatment's efficacy for severe congestive heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/english/. Unique identifier: UMIN000003273. John Wiley and Sons Inc. 2017-04-05 /pmc/articles/PMC5532985/ /pubmed/28381469 http://dx.doi.org/10.1161/JAHA.116.003918 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Miyagawa, Shigeru
Domae, Keitaro
Yoshikawa, Yasushi
Fukushima, Satsuki
Nakamura, Teruya
Saito, Atsuhiro
Sakata, Yasushi
Hamada, Seiki
Toda, Koichi
Pak, Kyongsun
Takeuchi, Masahiro
Sawa, Yoshiki
Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title_full Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title_fullStr Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title_full_unstemmed Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title_short Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy
title_sort phase i clinical trial of autologous stem cell–sheet transplantation therapy for treating cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532985/
https://www.ncbi.nlm.nih.gov/pubmed/28381469
http://dx.doi.org/10.1161/JAHA.116.003918
work_keys_str_mv AT miyagawashigeru phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT domaekeitaro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT yoshikawayasushi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT fukushimasatsuki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT nakamurateruya phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT saitoatsuhiro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT sakatayasushi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT hamadaseiki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT todakoichi phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT pakkyongsun phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT takeuchimasahiro phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy
AT sawayoshiki phaseiclinicaltrialofautologousstemcellsheettransplantationtherapyfortreatingcardiomyopathy